Compare McKesson Corporation (MCK) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Annaly Capital Management, Inc. — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B). The key difference: McKesson Corporation is far larger — about 7.9× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Annaly Capital Management, Inc. for 91 Days on average.
| MCK | NLY | |
|---|---|---|
Market Cap | $108.46B | $13.77B |
Volume | 712,607 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $995.69 | $24.40 |
52-Week Low | $725.17 | $17.93 |
Typical Hold Time | 74 Days | 91 Days |
Enterprise Value | $115.00B | $135.80B |
Dividend Yield | 0.4% | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
NLY trades at $18.27, up 1.9% with strong earnings momentum after beating estimates for three consecutive quarters. The stock offers a compelling 16.4% dividend yield with a recent increase to $0.75 per share. Valuation appears attractive with a P/E of 4.41 and P/B of 0.91, though technical indicators show bearish momentum. The company has demonstrated portfolio expansion from $73B in 2023 to $107B in 2026, driving earnings growth.
NLY presents a high-yield opportunity with discounted valuation and consistent earnings beats, but faces interest rate sensitivity and technical headwinds. The 57% analyst buy rating and $22 consensus target suggest 20% upside potential, though investors must weigh the attractive yield against mortgage REIT volatility and recent price weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
